Zacks Research cut shares of Envista (NYSE:NVST – Free Report) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks reports.
A number of other analysts have also recently issued reports on the company. Barclays lowered their price objective on Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, June 11th. UBS Group reduced their target price on Envista from $30.00 to $27.00 and set a “neutral” rating for the company in a research report on Friday, September 18th. Mizuho set a $29.00 price target on shares of Envista in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised shares of Envista from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $29.00 to $32.00 in a report on Thursday, September 3rd. Finally, BMO Capital Markets dropped their price objective on shares of Envista from $29.00 to $26.00 and set a “market perform” rating for the company in a research note on Monday, September 28th. Seven analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $29.79.
Read Our Latest Research Report on NVST
Envista Stock Performance
Envista (NYSE:NVST – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. During the same quarter in the previous year, the business earned $0.26 EPS. The business’s revenue was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts forecast that Envista will post 1.53 earnings per share for the current fiscal year.
Insider Activity
In other Envista news, SVP Mischa Reis sold 8,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the transaction, the senior vice president owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. This represents a 22.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.99% of the company’s stock.
Institutional Trading of Envista
Institutional investors have recently bought and sold shares of the business. QRG Capital Management Inc. acquired a new stake in shares of Envista during the second quarter worth $216,000. Envestnet Portfolio Solutions Inc. boosted its stake in Envista by 1.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 51,873 shares of the company’s stock worth $1,367,000 after purchasing an additional 941 shares during the period. Tidal Investments LLC boosted its stake in Envista by 2.4% in the 2nd quarter. Tidal Investments LLC now owns 23,555 shares of the company’s stock worth $621,000 after purchasing an additional 547 shares during the period. WINTON GROUP Ltd increased its holdings in Envista by 247.9% during the 2nd quarter. WINTON GROUP Ltd now owns 192,055 shares of the company’s stock worth $5,061,000 after purchasing an additional 136,855 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in Envista during the 2nd quarter worth about $210,000.
About Envista
Envista Holdings Corporation (NYSE: NVST) is a global dental-products and technologies company that develops, manufactures and markets equipment, consumables and digital solutions for dental professionals, laboratories and specialists. Its offerings support diagnosis, treatment planning, restorative dentistry, orthodontics, implant dentistry and related clinical procedures.
The company’s portfolio includes dental imaging systems and software, treatment units, handpieces, infection-control products, restorative materials, endodontic products, orthodontic brackets and aligners, dental implants, prosthetic components and laboratory solutions.
Recommended Stories
- Five stocks we like better than Envista
- The AI Boom’s Next Big Winners May Wear Hard Hats
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
- Allient’s Data Center and Defense Momentum Is Raising the Stakes
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
